Citius Pharmaceuticals, Inc. short interest in 2024
In 2024, Citius Pharmaceuticals, Inc.'s disclosed short interest ran from 8.77% of shares outstanding on 12 Jan 2024 to 7.70% on 31 Dec 2024, a change of -1.07 percentage points. The year's high was 9.08% on 30 Apr 2024 and its low 6.52% on 31 Oct 2024, averaging 7.65% across 22 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 23.79 days on 12 Jan 2024. Full history: Citius Pharmaceuticals, Inc..
Cite this page
By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2024 in figures
- Start of year
- 8.77% (12 Jan 2024)
- End of year
- 7.70% (31 Dec 2024)
- Change
- -1.07 pp
- High
- 9.08% (30 Apr 2024)
- Low
- 6.52% (31 Oct 2024)
- Average
- 7.65%
- Highest days to cover
- 23.79 (12 Jan 2024)
- SEC filings marked
- 9
Every report in 2024
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 12 Jan 2024 | 8.77% | 23.79 | results (8-K) |
| 31 Jan 2024 | 7.31% | 14.03 | |
| 15 Feb 2024 | 7.29% | 16.06 | 10-Q filed, results (8-K) |
| 29 Feb 2024 | 7.46% | 21.21 | |
| 15 Mar 2024 | 7.66% | 21.65 | |
| 28 Mar 2024 | 7.82% | 17.66 | |
| 15 Apr 2024 | 8.30% | 12.90 | |
| 30 Apr 2024 | 9.08% | 9.25 | |
| 15 May 2024 | 8.02% | 11.34 | 10-Q filed, results (8-K) |
| 31 May 2024 | 8.80% | 4.67 | |
| 14 Jun 2024 | 8.56% | 19.70 | |
| 28 Jun 2024 | 7.83% | 4.65 | |
| 15 Jul 2024 | 6.64% | 4.24 | |
| 31 Jul 2024 | 8.10% | 6.34 | |
| 15 Aug 2024 | 6.80% | 3.94 | 10-Q filed, results (8-K) |
| 30 Aug 2024 | 7.41% | 12.97 | |
| 13 Sep 2024 | 6.93% | 20.69 | |
| 30 Sep 2024 | 7.07% | 11.21 | |
| 15 Oct 2024 | 6.87% | 11.44 | |
| 31 Oct 2024 | 6.52% | 17.55 | |
| 15 Nov 2024 | 7.44% | 4.36 | |
| 31 Dec 2024 | 7.70% | 2.57 | 10-K filed, results (8-K) |
See also: Citius Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2024 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.